Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Irinotecan Sucrosofate

Review the clinical trials studying irinotecan sucrosofate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 146 locations
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: 17 locations
Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan for the Treatment of Previously Treated Advanced Biliary Tract Cancer, NAPOLI-2 Study
Status: Active
Location: 4 locations
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Status: Active
Location: 4 locations
Fluorouracil, Oxaliplatin, and Liposomal Irinotecan with or without Trastuzumab, Nivolumab, and Pembrolizumab for the First Line Treatment of Advanced Esophageal or Gastric Adenocarcinoma
Status: Active
Location: 4 locations
TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Location: 3 locations
Nanoliposomal Irinotecan plus Oxaliplatin with Fluorouracil and Folinic Acid for the Treatment of Unresectable or Metastatic Small Bowel Cancer
Status: Active
Location: 2 locations
Chemotherapy and Radiation with or without Liposomal Irinotecan using Molecular Risk for the Treatment of Children with Rhabdomyosarcoma
Status: Active
Location: 2 locations
NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Status: Active
Location: 2 locations
Intraperitoneal Paclitaxel with NALIRIFOX for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Sotorasib in Combination with Chemotherapy for Second Line Treatment of KRAS G12C Mutated Metastatic or Unresectable Pancreatic Cancer
Status: Approved
Location: Northwestern University, Chicago, Illinois
Onivyde in Combination with Talazoparib or Temozolomide for the Treatment of Recurrent or Refractory Solid Tumors and Ewing Sarcoma
Status: Temporarily Closed to Accrual
Location: 6 locations